BCAS2 is a ubiquitously expressed nuclear protein that was originally identified as being overexpressed in various breast cancer cell lines. BCAS2 is now known to be a component of the spliceosome, participating in the removal of introns from mRNA precursors. BCAS2 specifically interacts (in a ligand-independent manner) with thyroid hormone receptor beta, ER alpha (estrogen receptor alpha), PR (progesterone receptor), and PPAR gamma (Peroxisome proliferator-activated receptor gamma). BCAS2 functions as an ER coactivator and is capable of enhancing ER-mediated transcription. This suggests that BCAS2 is involved in the development of breast cancer.
Function:
Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core complex.
Subunit:
Component of the PRP19-CDC5L splicing complex composed of a core complex comprising a homotetramer of PRPF19, CDC5L, PLRG1 and BCAS2, and at least three less stably associated proteins CTNNBL1, CWC15 and HSPA8. Interacts directly in the complex with PRPF19, CDC5L and PLRG1.
Subcellular Location:
Nucleus, nucleolus.
Tissue Specificity:
Ubiquitously expressed.
Similarity:
Belongs to the SPF27 family.
SWISS:
O75934
Gene ID:
10286
Database links:
Entrez Gene: 10286 Human
Entrez Gene: 68183 Mouse
Entrez Gene: 295334 Rat
Omim: 605783 Human
SwissProt: O75934 Human
SwissProt: Q9D287 Mouse
Unigene: 22960 Human
Unigene: 104919 Mouse
Unigene: 1225 Rat
|
|
